Trade Moderna

Moderna (mа-DUR-née) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and RNA messenger-based vaccine technologies (PASS). Moderna's technology platform introduces synthetic nucleoside modRNA into human cells. This flexible then reprogramthe cells to demand immune responses. It is a new technique, which has already been abandoned due to the side effects of introducing a flexible into cells. As of November 2020, the candidate of the Covid-19 Modrana vaccine, MRNA-1273, has shown preliminary evidence of 94% efficacy in the prevention of COVID-19 disease in the phase III trial, with only minor influenza-like side effects. This led to her submission of an emergency use permit (EUA) in Europe, the United States and Canada. On December 18, 2020, THE EU MRNA-1273 was released in the United States. It was authorized to be used in Canada on December 23, 2020, as well as in the European Union on January 6, 2021. Subsequently, the use of MRNA-1273 was authorized in the United Kingdom on 8 January 2021.